Trump Officials Push Pharma to Onshore Generic Drug Production
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Marco Rubio, Robert F. Kennedy Jr., and HHS Chief Counsel Chris Klomp met with pharmaceutical leaders last week in the Eisenhower Executive Office Building, next to the White House
- The administration's message to industry: bring production of essential medications back to the U.S. — or at least closer to home
- The meeting focused on increasing U.S. control of supply chains for the 86 medicines deemed essential by HHS's Assistant Secretary for Preparedness and Response
- Details of the meeting were described by an administration official and two people familiar with the event
- The gathering signals a coordinated push across State, HHS leadership, and HHS legal counsel to engage drugmakers on reshoring essential generic production
Why it matters: The onshoring push is anchored to a specific list of 86 essential medicines, meaning any resulting policy would target a defined set of generic drug supply chains — directly affecting the manufacturers of those drugs and the hospitals and patients who depend on their availability and pricing.
